Establishment of CHO cell lines expressing four N-methyl-D-aspartate receptor subtypes and characterization of a novel antagonist PPDC  by Uchino, Shigeo et al.
Establishment of CHO cell lines expressing four
N-methyl-D-aspartate receptor subtypes and characterization
of a novel antagonist PPDC
Shigeo Uchinoa;*, Wakako Watanabeb, Takeshi Nakamurac, Satoshi Shutod, Yuji Kazutad,
Akira Matsudad, Sadayo Nakajima-Iijimab, Yoshihisa Kudoc, Shinichi Kohsakaa,
Masayoshi Mishinae
aDepartment of Neurochemistry, National Institute of Neuroscience, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, Japan
bPharmaceuticals Discovery Laboratory, Yokohama Research Center, Mitsubishi-Tokyo Pharmaceuticals Inc., 1000 Kamoshida, Aoba-ku,
Yokohama 227-8502, Japan
cDepartment of Cellular Neurobiology, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0355, Japan
dGraduate School of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan
eDepartment of Molecular Neurobiology and Pharmacology, School of Medicine, University of Tokyo, Tokyo 113-0033, Japan
Received 23 August 2001; accepted 4 September 2001
First published online 18 September 2001
Edited by Maurice Montal
Abstract To develop an assay system that allows the N-methyl-
D-aspartate (NMDA) receptor subtype-selective antagonistic
potency of drugs, we have established Chinese hamster ovary
cell lines expressing the four NMDA receptor subtypes (GluRO1/
j1^GluRO4/j1) heat-indelibly. Using these clonal cells, we found
that a novel antagonist, (1S,2R)-1-phenyl-2[(S)-1-aminopropyl]-
N,N-diethylcyclopropanecarboxamide, was less selective for the
GluRO1/j1: the IC50 values for the GluRO1/j1^GluRO4/j1 were
41.7, 13.3, 12.6 and 11.5 WM, respectively, while two well-known
antagonists, DL-2-amino-5-phosphonovaleric acid and ifenprodil,
showed the known potency and selectivity for each subtype. Thus,
the established clonal cells are of use in characterizing the
pharmacological properties of drugs that act on NMDA
receptors. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The N-methyl-D-aspartate (NMDA) subtype of the gluta-
mate receptor (GluR) plays a key role in synaptic plasticity as
a molecular coincidence detector [1,2]. Studies using speci¢c
antagonists have demonstrated that NMDA receptors play
diverse physiological roles in learning, memory and neural
development [3]. NMDA receptors are composed of GluRO
(NR2) and GluRj (NR1) subunits [4^6]. The GluRO subunit
contains the glutamate binding site, while the GluRj subunit
bears the glycine binding site [7,8]. There are four GluRO sub-
unit genes [4^6,9] and a single GluRj subunit gene [10,11].
Expression of the four GluRO subunit genes varies depending
on brain regions and developmental stages. The four GluRO
subunits also di¡er in terms of functional properties and mod-
ulations and are the key determinants of NMDA receptor
diversity [12,13]. The physiological signi¢cance of the molec-
ular diversity of the NMDA receptor has been examined by
gene-targeting techniques. Disruption of the GluRO1 gene re-
sults in increased thresholds for hippocampal long-term po-
tentiation and contextual learning [14,15]. GluRO2 mutant
mice failed to form the whisker-related neural pattern (barre-
lettes) in the brainstem trigeminal complex [16], as do GluRj1
mutant mice [17]. Ablation of the GluRO2 subunit di¡eren-
tially a¡ects plasticity at various hippocampal synapses
[16,18]. GluRO4 mutant mice exhibited reduced spontaneous
activity [19], while the combination of a GluRO1 and a GluRO3
mutation in mice results in a motor de¢cit [20,21]. GluRO1
and GluRO4 di¡erentially contributed to pain modulation
[22].
Excessive activation of the NMDA receptor may lead to
excessive increase in intracellular Ca2 concentration
([Ca2]i) followed by neurodegeneration [23]. Thus, NMDA
receptor antagonists would be useful to protect neurons from
brain diseases, such as epilepsy, stroke, ischemia and Parkin-
son’s syndrome [24^26]. However, NMDA receptor antago-
nists may have various adverse side e¡ects, especially psycho-
tomimetic e¡ects and motor impairment [27,28]. The
availability of subtype-selective drugs may minimize the ad-
verse side e¡ects of NMDA receptor antagonists. In fact, the
GluRO2 subunit-selective antagonists, CP-101,606 and its de-
rivatives suppress mechanical hyperalgesia and inhibit capsai-
cin- and 4L-phorbol-12-myristate-12-acetate-induced nocicep-
tive responses without producing any behavioral side e¡ects
[29]. It would therefore be useful to develop an assay system
of the subtype-selective antagonistic potency of drugs. One
approach is to establish recombinant cell lines expressing dif-
ferent subtypes of the NMDA receptor. Previously, we estab-
lished Chinese hamster ovary (CHO) cell lines that expressed
GluRO1/j1 NMDA receptors following heat induction [30].
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Here, we extend this approach to the GluRO2/j1, GluRO3/j1,
and GluRO4/j1 subtypes of the NMDA receptor.
2. Materials and methods
2.1. Plasmid construction
cDNA fragments containing the entire coding sequences of the
GluRj1 subunit (3.2 kb ApaI fragment, nucleotide residues 3124^
3029), GluRO1 subunit (4.4 kb NcoI^XbaI fragment, nucleotide resi-
dues 366^4329), GluRO2 subunit (4.5 kb SalI^BamHI fragment, nu-
cleotide residues 393^4438), GluRO3 subunit (3.6 kb SacI^NcoI frag-
ment, nucleotide residues 3156^3801) and GluRO4 subunit (4.2 kb
SalI^EcoRI fragment, nucleotide residues 381^4078) were prepared.
Each fragment was inserted into the SalI site downstream of the
Drosophila heat shock protein (hsp) 70 promoter in the pHSD mam-
malian expression vector [30] using blunt-end ligation to yield pHSD-
j1, pHSD-O1, pHSD-O2, pHSD-O3 and pHSD-O4.
2.2. Cell culture, DNA transfection and isolation of clonal cells
CHO cells were maintained at 37‡C in eRDF-1 medium [30] sup-
plemented with 10% fetal bovine serum (FBS) in a humidi¢ed atmos-
phere containing 5% CO2.
For transfection, exponentially growing cells were trypsinized,
seeded in six-well plates at 2U105 cells/well, incubated overnight in
eRDF-1 medium supplemented with 10% FBS, then transfected with
15 Wg of DNA using the lipopolyamine-mediated procedure, and
maintained in selective growth medium [30]. The selective growth
media used were eRDF-1 medium containing 10% FBS, 1200 Wg/ml
of geneticin, 2 Wg/ml of blasticidin S hydrochloride, 10 Wg/ml of pur-
omycin and 200 WM DL-2-amino-5-phosphonovaleric acid (DL-APV), a
speci¢c competitive antagonist of the NMDA receptor added to pre-
vent toxicity due to possible stress-induced leaky expression of
NMDA receptors. After about 2 weeks, antibiotic-resistant colonies
were picked for expansion and each resistant colony was grown up in
two culture dishes. One dish, containing 50^80% con£uent cells, was
incubated at 43‡C for 2 h, then total RNA was immediately extracted
to study NMDA receptor mRNA expression, while the other dish was
subcultured continuously and tested for functional NMDA receptors
by calcium £uorometry. The clonal cells were recloned by limiting
dilution.
2.3. Heat induction
CHO cells, plated in selective growth medium at a density of 1.5^
2.5U104 cells/cm2 in 100 mm culture dishes for immunoblot experi-
ments and on collagen-coated glass coverslips with a silicon rubber
wall (Flexiperm Disc) for calcium imaging, were incubated at 37‡C for
24^36 h. They were then incubated at 43‡C for 2 h and maintained at
37‡C for the indicated periods in the appropriate selective growth
medium containing 1 mM DL-APV.
2.4. Immunoblot analysis
CHO cells were lysed in 0.1 M Na2CO3 on ice, then pelleted by
centrifugation at 18 000Ug for 10 min at 4‡C. The pellets were sus-
pended in 50 mM Tris^HCl (pH 7.4), 0.3 mM EDTA, 1 mM dithio-
threitol and 1 mM phenylmethanesulfonyl £uoride, then boiled for
5 min with an equal volume of SDS^PAGE sample bu¡er. The proteins
were separated by electrophoresis through a 2^15% gradient SDS
polyacrylamide gel (Daiichi Pure Chemicals), then electrophoretically
transferred onto polyvinylidene di£uoride membranes. To detect the
GluRO1, GluRO2, GluRO3 and GluRj1 subunits, the membranes were
blocked by incubation for 2 h at room temperature with 5% dried
skimmed milk in phosphate-bu¡ered saline (PBS), then incubated
overnight at 4‡C with the appropriate primary rabbit antibody (2.0
Wg/ml of anti-NMDAR2A, 1.3 Wg/ml of anti-NMDAR2B, 2.0 Wg/ml
of anti-NMDAR2C or 1.0 Wg/ml of anti-NMDAR1A; Chemicon),
diluted in PBS containing 0.1% Tween (PBS-T). To detect the GluRO4
subunit, the membranes were blocked by incubation for 16 h at 4‡C
with 5% dried skimmed milk in PBS-T, then incubated for 1 h at
room temperature with 3.0 Wg/ml of rabbit anti-GluRO4 antibody
provided by Dr. K. Sakimura, Niigata University. After rinsing
with PBS-T, the blots were incubated with a 1:1000 dilution of horse-
radish peroxidase-conjugated goat anti-rabbit IgG (Medical and Bio-
logical Lab.) and reactive bands visualized using an enhanced chem-
iluminescence system (Amersham).
2.5. Measurement of [Ca2+]i
CHO cells were plated at a density of 1.5^2.5U104 cells/cm2 in
selective growth medium on collagen-coated glass coverslips and in-
cubated sequentially at 37‡C for 24^36 h and 43‡C for 2 h, then
maintained at 37‡C for the indicated periods before measuring the
[Ca2]i as described below.
CHO cells were incubated for 45 min with 5.0 WM fura-2 acetox-
ymethyl ester, dispersed by brief sonication in balanced salt solution
(BSS), consisting of 130 mM NaCl, 5.4 mM KCl, 2.0 mM CaCl2, 5.5
mM glucose and 10 mM HEPES (pH 7.3), supplemented with 0.001%
cremophore EL (a solubility enhancer). The fura-2-loaded cells were
then placed on the stage of an inverted £uorescence microscope
(IX50; Olympus) and perfused with BSS at a rate of 2.0 ml/min.
Using alternate illumination at 340 and 380 nm excitation, £uores-
cence images were obtained using a magni¢cation objective lens
(UApo 20U/340; Olympus) and an emission ¢lter (510^550 nm), cap-
tured using a silicon-intensi¢ed-target video camera (C2400-8; Hama-
matsu Photonics), digitized using an image processor (Argus 50/CA;
Hamamatsu Photonics) and the data fed into a personal computer
(Venturis FXs, Digital). For ratiometry, ratio images were obtained
by dividing the £uorescence intensity at 340 nm excitation (F340) by
that at 380 nm excitation (F380) using the computer and the image
processor. The cytosolic free Ca2 concentration was estimated from a
calibration curve of fura-2 £uorescence ratio (F340/F380) versus Ca2
concentration, established using dilutions of a Ca2 solution of
known concentration (Calcium Calibration Bu¡er kit with Magnesi-
um I; Molecular Probes) containing 30 WM fura-2 free acid and the
same optical settings as those used for the CHO cells.
2.6. Data analysis
Concentration^inhibition curves were ¢tted by the logistic equa-
tion:
I=I control  1=f1 antagonist=IC50ng;
where Icontrol is the response in the absence of the antagonist, IC50 is
the concentration of the drug that inhibits 50% of this response and n
is the Hill coe⁄cient.
IC50 values for DL-APV were corrected for L-glutamate a⁄nity ac-
cording to the equation:
IC50  IC50=f1 Lÿ glutamate=EC50g;
where IC50* is the measured value obtained from the inhibition curve,
[L-glutamate] is 100 WM and the EC50 values for L-glutamate are 1.7,
0.8, 0.7, and 0.4 WM for the GluRO1/j1, GluRO2/j1, GluRO3/j1, and
GluRO4/j1 subtypes, respectively [13].
3. Results
3.1. Establishment of CHO cell lines expressing NMDA
receptor subtypes upon heat induction
We placed the respective GluRO subunit cDNAs under the
control of Drosophila hsp70 gene promoter in the pHSD ex-
pression vector. To establish a cell line expressing the GluRO2/
j1 subtype, plasmids pHSD-O2 and pSV2brs carrying the blas-
ticidin S hydrochloride resistance gene were co-transfected
into Z1-1 CHO cells carrying the heat-inducible GluRj1 ex-
pression vector pHSD-j1 [30]. Resulting geneticin- and blas-
ticidin S hydrochloride-resistant clones were screened for the
heat-inducible expression of GluRO2 mRNA by RNA blot
hybridization analysis. Further screening for functional
NMDA receptor expression by measuring 100 WM L-gluta-
mate plus 100 WM glycine-inducible [Ca2]i responses estab-
lished cell line ZE2-1. Further transfection of ZE2-1 cells with
pHSD-j1 and pSV2pur carrying the puromycin resistance
gene yielded E2 cell line, which expressed high levels of
GluRO2/j1 subtype NMDA receptors following heat induc-
tion. The E1 cell line expressing a high level of the GluRO1/
j1 subtype was produced similarly by transfection of ZE1-1
cells with pHSD-j1.
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To establish cell lines expressing the GluRO3/j1 and
GluRO4/j1 subtypes, we ¢rst isolated the Z1 cell line by co-
transfecting CHO cells with pHSD-j1 and pSV2neo. RNA
blot hybridization showed that Z1 cells expressed more
GluRj1 mRNA than the previously produced Z1-1 cells
(data not shown). Z1 cells were then transfected with
pHSD-O3 or pHSD-O4 expression vector. Screening of result-
ing clones established E3 and E4 cell lines, which, respectively,
produced high levels of the GluRO3/j1 and GluRO4/j1 sub-
types following heat induction.
The growth rates and shapes of the heat-induced and non-
heat-induced cells were indistinguishable. The inducible ex-
pression of functional NMDA receptors in an established
cell line was stable for at least 25 passages.
3.2. Heat-inducible expression of NMDA receptor subtypes
To study the heat-inducible expression of subunit proteins,
membrane fractions were prepared from cells cultured for 6 h
after heat induction. Fig. 1 shows immunoblot analyses of the
subunits produced in the cell lines. The molecular masses of
the GluRj1 (115 kDa; Fig. 1B), GluRO1 (170 kDa; Fig. 1C),
GluRO2 (170 kDa; Fig. 1D), GluRO3 (130 kDa; Fig. 1E) and
GluRO4 (140 kDa; Fig. 1F) subunits are in good agreement
with those determined for the respective subunits in mouse
Fig. 1. Heat-inducible expression of GluRj1, GluRO1, GluRO2, GluRO3, and GluRO4 subunits in clonal cells. Proteins were separated by elec-
trophoresis through a 2^15% gradient SDS polyacrylamide gel and stained with Coomassie brilliant blue (A). Molecular weight standards (42^
200 kDa; Daiichi Pure Chemicals) are indicated on the left. The separated proteins were transferred and detected using NMDAR1A (B),
NMDAR2A (C), NMDAR2B (D), NMDAR2C (E) or GluRO4 (F) antibodies. Lane 1: sample prepared from 1.5U106 CHO cells; lane 2:
sample prepared from 3.6U105 Z1 cells; lane 3: sample prepared from 3.6U105 E1 cells; lane 4: sample prepared from 1.5U106 E2 cells; lane
5: sample prepared from 7.2U105 E3 cells; lane 6: sample prepared from 7.2U105 E4 cells. The expected molecular weight for each subunit is
indicated on the right.
Fig. 2. [Ca2]i responses to L-glutamate plus glycine in clonal cells. After heat induction, Z1, E1 and E2 cells were incubated for 6 h at 37‡C,
while E3 and E4 cells were incubated for 10 h at 37‡C. The upper (3Glu/Gly) and lower (+Glu/Gly) panels show images of the cells before
and after 100 WM L-glutamate plus 100 WM glycine application, respectively. The corresponding values of the [Ca2]i are given by the color
scale on the right.
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brain. No subunit proteins were detectable in non-induced
cells or control CHO cells.
We examined the expression of functional NMDA recep-
tors by measuring the [Ca2]i increase in response to 100 WM
L-glutamate plus 100 WM glycine. As shown in Fig. 2, the E1,
E2, E3 and E4 cell lines, but not Z1 cells, showed clear [Ca2]i
responses 6^10 h after heat induction. Virtually no responses
were seen in Ca2-free BSS (data not shown), indicating that
the [Ca2]i increase was due to the Ca2 in£ux into the cells.
No responses were detectable in the absence of heat induction
(data not shown).
3.3. Sensitivity to DL-APV and ifenprodil of NMDA receptor
subtypes expressed in CHO cell lines
The heat-induced cells showed reproducible [Ca2]i re-
sponses to repeated applications of 100 WM L-glutamate plus
100 WM glycine (applications for 30 s with an interval of 15
min) (Fig. 3). Thus, the expressed NMDA receptors showed
little desensitization under these experimental conditions. Us-
ing these clonal cell lines and calcium £uorometry, we inves-
tigated the antagonistic potency and subtype selectivity of the
typical antagonists, DL-APV and ifenprodil. We ¢rst measured
the [Ca2]i response to 100 WM L-glutamate plus 100 WM gly-
cine for 30 s. After washing with BSS for 15 min, we applied
antagonist for 30 s, antagonist and L-glutamate plus glycine
for 30 s, and then antagonist for 30 s successively. After wash-
ing with BSS for 15 min, we applied L-glutamate plus glycine
for 30 s to examine the recovery of the response.
DL-APV inhibited the responses of all four cell lines with
varying e⁄ciency (Fig. 4A). Since the four NMDA receptor
subtypes have di¡erent a⁄nities for L-glutamate [19], the IC50
values obtained from inhibition curves were corrected for
L-glutamate a⁄nity in order to examine the subtype sensitivity
[31]. The corrected IC50 values of DL-APV for the GluRO1/j1,
GluRO2/j1, GluRO3/j1 and GluRO4/j1 subtypes were
0.88 þ 0.03 WM (n = 3), 1.45 þ 0.10 WM (n = 3), 2.39 þ 0.03
WM (n = 3) and 17.5 þ 1.5 WM (n = 3), respectively. The Hill
coe⁄cient values for the GluRO1/j1, GluRO2/j1, GluRO3/j1
and GluRO4/j1 subtypes were 1.2 þ 0.04, 1.0 þ 0.1, 1.2 þ 0.1
and 0.8 þ 0.03, respectively. The rank order of sensitivity to
DL-APV was GluRO1/j1sGluRO2/j1sGluRO3/j1sGluRO4/
Fig. 3. [Ca2]i responses of clonal cells to three successive applica-
tions of L-glutamate plus glycine. Kinetic traces for the evoked
Ca2 signals are shown for Z1 cells (A), E1 cells (B), E2 cells (C),
E3 cells (D) and E4 cells (E). After heat induction, the Z1, E1 and
E2 cells were incubated for 6 h at 37‡C, while the E3 and E4 cells
were incubated for 10 h. The 30 s applications of 100 WM L-gluta-
mate plus 100 WM glycine are indicated by arrows. The data are the
mean values for seven individual cells.
Fig. 4. Inhibitory e¡ects of DL-APV (A), ifenprodil (B) and PPDC
(C) on the [Ca2]i responses to 100 WM L-glutamate plus 100 WM
glycine (A, B) or 30 WM L-glutamate plus 30 WM glycine (C). After
heat induction, the cells were incubated for 6^10 h at 37‡C. Data
were done in triplicate and shown as mean þ S.D. The structure of
PPDC is shown in the insert.
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j1 subtypes, in accordance with the previous studies by the
Xenopus oocyte expression system [13,31].
Ifenprodil is a GluRO2/j1 subtype-selective antagonist act-
ing at the polyamine modulatory site [32]. As expected, the
GluRO2/j1 subtype was highly sensitive to ifenprodil (IC50 :
0.35 þ 0.03 WM, Hill coe⁄cient: 2.0 þ 0.2, n = 3), whereas con-
centrations greater than 100 WM were required to a¡ect the
responses of E1, E3 and E4 cells (Fig. 4B).
3.4. Characterization of the subtype selectivity of a novel
NMDA antagonist using the cell lines
(1S,2R)-1-Phenyl-2[(S)-1-aminopropyl]-N,N-diethylcyclopro-
panecarboxamide (PPDC) is a novel non-competitive NMDA
receptor antagonist [33]. We investigated the antagonistic po-
tency and subtype selectivity of PPDC using the established
CHO cell lines. The inhibitory e¡ects of PPDC on the [Ca2]i
responses of the cell lines to 30 WM L-glutamate plus 30 WM
glycine are shown in Fig. 4C. The IC50 values of PPDC for
the GluRO1/j1, GluRO2/j1, GluRO3/j1 and GluRO4/j1 sub-
types were 41.7 þ 1.5 WM (Hill coe⁄cient: 0.9 þ 0.1, n = 3),
13.3 þ 0.5 WM (1.1 þ 0.1, n = 3), 12.6 þ 0.5 WM (1.0 þ 0.1,
n = 3) and 11.5 þ 1.2 WM (1.0 þ 0.1, n = 3), respectively. The
e¡ect of PPDC was essentially reversible and lost after a
15 min washing.
4. Discussion
Extensive studies have been performed to characterize the
properties and selectivity of various NMDA receptor ligands
using brain slices and cultured neurons [34,35]. Because of
possible heterogeneity in terms of cell type and receptor sub-
type, such studies are of limited use in the precise determina-
tion of the characterization and subtype speci¢city of NMDA
receptor ligands. The four GluRO subunits carrying the gluta-
mate binding site of the NMDA receptor are distinct in terms
of distribution, functional properties and modulation. Tran-
sient expression of NMDA receptors in Xenopus oocytes
[13,31] and HEK293 cells [6,36,37] has been used to examine
their pharmacological properties. However, these approaches
are less convenient and reproducible for drug assays on a
regular basis than a permanent expression system, such as a
stably transfected cell line. Thus, the availability of recombi-
nant cells expressing these subtypes of the NMDA receptor
would be useful in their characterization and in the develop-
ment of subtype-selective drugs. Constitutive expression of
exogenous NMDA receptors, however, is toxic to host cells
[38,39]. In previous studies, a dexamethasone-inducible pro-
moter [40^42] and a tetracycline sensitive transactivator sys-
tem [43] were used to express the GluRO1/j1 and GluRO2/j1
subtypes. In the present study, we used an expression vector
containing the inducible Drosophila hsp70 promoter to express
NMDA receptors in CHO cells. Using this approach, we have
successfully established clonal CHO cell lines expressing re-
spective subtypes of the NMDA receptor upon heat induc-
tion.
After heat induction, we observed a signi¢cant increase in
the L-glutamate plus glycine-evoked [Ca2]i response in more
than 80% of E1 cells and about 50% of E2, E3 and E4 cells.
This result, together with those of the Western blot analyses in
which the strongest signal was seen with E1 cells, shows that
E1 cells produce a higher level of functional NMDA receptors
compared with the other clonal cells. In order to increase the
percentage of cells expressing functional NMDA receptors
and the expression level of functional NMDA receptors, re-
cloning by limiting dilution and/or re-introduction of subunit
cDNAs into E2, E3 or E4 cells would probably be useful
approaches. Interestingly, despite the fact that expression of
subunit proteins was lower in E2 cells than in E3 or E4 cells,
the peak of the L-glutamate plus glycine-induced response in
E2 cells was higher than in E3 or E4 cells, and almost as high
as in E1 cells. This result was in agreement with that of
Northern blot analysis in which the weakest signal was seen
with E2 cells (data not shown). One explanation for this dis-
crepancy would be the di¡erence in Ca2 permeability be-
tween NMDA receptor subtypes. The Ca2/Cs permeability
ratio is lower for GluRO3/j1 than for GluRO1/j1 [37], while
GluRO1/j1 and GluRO2/j1 have similar Ca2 permeability
[44]. In addition, functional expression of similar amounts
of GluRO1/j1 or GluRO2/j1, but not GluRO3/j1, resulted in
cell death, and the authors suggested that this di¡erence in
vulnerability was due to di¡erences in Ca2 permeability be-
tween the NMDA receptor subtypes [39].
Whole cell recording and binding assays have been conven-
tionally used to characterize drugs. However, whole cell re-
cording is not amenable to a high throughput. Binding assays
require relatively large amounts of puri¢ed receptor-contain-
ing membranes, are restricted by the availability of suitable
radioactive ligands, and are not functional assays. In contrast,
the digital calcium imaging technique can be easily used for
functional analysis of receptors, and advanced machinery for
this technique has recently been developed, allowing high
throughput. Moreover, in HEK293 cells, the IC50 value for
toxicity is reported to be closer to the IC50 value measured by
calcium £uorometry than to that measured by ligand binding
experiments [45]. In the present study, we therefore employed
the digital calcium imaging technique using the dye fura-2, in
a model study of the e¡ects on the four NMDA receptor
subtypes of two well-characterized NMDA receptor antago-
nists, DL-APV and ifenprodil, and a novel antagonist, PPDC.
Since three successive administrations of agonists were
found to induce comparable responses, it was possible to
study antagonistic potency and reversibility of e¡ects in a
precise manner. The four NMDA receptor subtypes showed
di¡erential sensitivity to DL-APV. The corrected IC50 values of
DL-APV were 0.88 þ 0.03 WM for GluRO1/j1, 1.45 þ 0.10 WM
for GluRO2/j1, 2.39 þ 0.03 WM for GluRO3/j1, 17.5 þ 1.48 WM
for GluRO4/j1. The observed rank order is in accordance with
that found in the Xenopus oocytes expression system [13,31].
The present study shows that the antagonistic e¡ect of ifen-
prodil was highly selective for GluRO2/j1, and the IC50 value
(0.35 þ 0.03 WM) was close to that obtained using GluRO2/j1
expressed in Xenopus oocytes (0.34 WM) [32]. These results
indicate that our system works properly in determining the
potency and selectivity of drugs.
In the present study, we also determined the sensitivity of
NMDA receptor subtypes to PPDC. PPDC is a conforma-
tionally restricted analog of milnacipran [33]. Although mil-
nacipran, a potent inhibitor of serotonin (5HT) uptake, sup-
presses the binding of MK-801 to NMDA receptors [46], its
structure is quite di¡erent from that of MK-801. Recent stud-
ies have shown that PPDC decreases the maximal responses to
both NMDA and glycine without altering their dissociation
constants. It has no e¡ects on the other GluR families
(AMPA, kainate and metabotropic GluRs) or on other neuro-
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transmitter receptors (GABAA, 5HT2C and acetylcholine re-
ceptors) [47]. Thus, PPDC is a speci¢c and non-competitive
antagonist for NMDA receptors. The present study shows
that PPDC had less e¡ect on the GluRO1/j1 subtype than
on other subtypes. Since stable cell lines and digital calcium
imaging technique will facilitate a rapid functional high
throughput assay, these CHO cell lines will provide a useful
tool for the development of NMDA receptor subtype-selective
drugs.
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